FindTrial
Sign In

Comparison between high and low doses and between two different intravenous administration modalities in patients with advanced heart failure.

Furosemide bolus versus continuous infusion in high risk acute decompensated heart failure: a randomized controlled trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2013-000866-12-IT
Enrollment
Unknown
Registered
2013-04-09
Start date
2013-06-04
Completion date
Unknown
Last updated
2014-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Heart Failure MedDRA version: 14.1 Level: LLT Classification code 10024106 Term: Left heart failure System Organ Class: 10007541 - Cardiac disorders MedDRA version: 14.1 Level: HLGT Classification code 10019280 Term: Heart failures System Organ Class: 10007541 - Cardiac disorders MedDRA version: 14.1 Level: LLT Classification code 10019285 Term: Heart failure, unspecified System Organ Class: 10007541 - Cardiac disorders MedDRA version: 14.1 Level: LLT Classification code 10019284 Te

Interventions

Trade Name: Lasix Product Name: Furosemide Pharmaceutical Form: Infusion INN or Proposed INN: FUROSEMIDE CAS Number: 54-31-9 Current Sponsor code: none Other descriptive name: none Concentration unit:

Sponsors

A. O. Città della Salute
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Advanced heart failure presenting: - systolic blood pressure =65 years) yes F.1.3.1 Number of subjects for this age range 10

Exclusion criteria

Exclusion criteria: - acute coronary syndrome - cardiogenic shock - chronic renal failure V stadium (creatinine clearance < 15 ml/min or dyalisis)

Design outcomes

Primary

MeasureTime frame
Main Objective: Evaluation of improvement of congestive status and renal function;Secondary Objective: Evaluation of neuro-ormonal profile;Primary end point(s): Evaluation of congestive status and urinary output;Timepoint(s) of evaluation of this end point: 24 and 48 hours—

Secondary

MeasureTime frame
Secondary end point(s): Evaluation of neuro-ormonal profile, ultrafiltration need, number of days to oral therapy and weight loss;Timepoint(s) of evaluation of this end point: 48 hours—

Countries

Italy

Contacts

Public ContactCardiologia U

A.O. Città della Salute

sbergerone@molinette.piemonte.it+390116335572

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026